THIS ANNOUNCEMENT CONTAINS INSIDE
INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF EU REGULATION 596/2014
AS IT FORMS PART OF DOMESTIC LAW IN THE UNITED KINGDOM BY VIRTUE OF
THE EUROPEAN UNION (WITHDRAWAL) ACT 2018. UPON THE PUBLICATION OF
THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INSIDE
INFORMATION WILL BE CONSIDERED TO BE IN THE PUBLIC
DOMAIN.
28 May 2024
Graft Polymer (UK)
Plc
("Graft Polymer" or the
"Company")
Filing of US Provisional
Patent for Substance Use Disorders Treatment
Graft Polymer (UK) Plc (LSE: GPL)
announces that it has filed a utility patent application
(provisional) with the United States Patent and Trademark Office
(USPTO) for the use of its proprietary and patented
self-nanoemulsifying drug delivery systems (SNEDDS) platform for
the delivery of drugs for the treatment of substance use
disorders.
Patent Filing Overview
The provisional patent application,
titled 'Composition and methods
for substance use disorders (SUDS) using a self-nanoemulsifying
drug delivery systems (SNEDDS)', covers the innovative
application of Graft Polymer's SNEDDS platform to enhance the
bioavailability, pharmacokinetics, and stability of therapeutics
used in the treatment of substance use disorders many of which have
poor solubility, leading to suboptimal drug delivery and posing an
obstacle to successful formulation. This approach aims to leverage
the Company's existing advanced biopolymer expertise to address
significant unmet medical needs in addiction therapy.
Strategic Significance
The filing of this patent marks
further progress in the Company's strategic focus on the healthcare
industry, following the disposal of its industrial plastic
manufacturing unit, Graft Polymer D.O.O, as announced on 3 May
2024. This disposal has enabled the Company to focus its attention
and resources on its Graft Bio division, which represents, in the
Directors' opinion, strong prospectivity through its
intellectual property (IP), licensing agreements, and sales
contracts.
Anthony Tennyson, CEO commented
"We are delighted to announce this
progress in leveraging our existing biopolymer intellectual
property for important healthcare applications with substantial
unmet medical needs."
Enquiries
Graft Polymer (UK) Plc
Anthony Tennyson, CEO and Executive Director
Email: anthonytennyson@graftpolymer.com
Yifat Steuer, CFO and Executive
Director
Email: yifat@graftpolymer.com
Allenby Capital (Broker)
Nick Naylor / Liz Kirchner
(Corporate Finance)
Guy McDougall
(Sales)
+44 (0) 20 3328
5656